Revlimid (lenalidomide) is a brand-name oral capsule that’s prescribed for certain types of myeloma, lymphoma, and anemia. As with other drugs, Revlimid can cause side effects, such as skin rash and ...
TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of a first generic ...
Rituximab and lenalidomide combination therapy shows promise for relapsed/refractory indolent non-Hodgkin lymphoma, with high response and remission rates. The AUGMENT trial demonstrated favorable ...
A phase 3 clinical trial evaluating the use of lenalidomide (Revlimid, Celgene) in 450 patients with chronic lymphocytic leukemia (CLL) has been stopped. The trial was exploring CLL as a new ...
Combination tafasitamab, lenalidomide, and rituximab is a recommended second-line regimen based on the phase 3 InMIND trial. The clinical data supporting the addition of tafasitamab to lenalidomide ...
RIO DE JANEIRO — The addition of daratumumab to lenalidomide maintenance therapy following autologous stem cell transplant (ASCT) significantly improves rates of achieving minimal residual disease ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window I presented the ...
BOSTON, Dec 1 (Reuters) - Sales of Celgene Corp's cancer drug Revlimid could rise by more than a third if data due to be presented next Monday at the annual meeting of the American Society of ...
A new study conducted by researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore has uncovered a key mechanism behind lenalidomide resistance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results